Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies</p>
Fiona H. Tan, Tracy L. Putoczki, Stanley S. Stylli, et al.
OncoTargets and Therapy (2019) Vol. Volume 12, pp. 635-645
Open Access | Times Cited: 164

Showing 1-25 of 164 citing articles:

Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Filipa Lopes‐Coelho, Filipa Martins, Sofia A. Pereira, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3765-3765
Open Access | Times Cited: 283
Molecular targeted therapy for anticancer treatment
Hye‐Young Min, Ho‐Young Lee
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1670-1694
Open Access | Times Cited: 258
Advances in covalent kinase inhibitors
Ayah Abdeldayem, Yasir S. Raouf, Stefan N. Constantinescu, et al.
Chemical Society Reviews (2020) Vol. 49, Iss. 9, pp. 2617-2687
Closed Access | Times Cited: 256
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente‐Macías, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 1047-1131
Open Access | Times Cited: 196
Assessing the impact of generative AI on medicinal chemistry
W. Patrick Walters, Mark A. Murcko
Nature Biotechnology (2020) Vol. 38, Iss. 2, pp. 143-145
Closed Access | Times Cited: 194
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 160
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Raquel Alves, Ana Cristina Gonçalves, Sergio Rutella, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4820-4820
Open Access | Times Cited: 121
Patient-derived xenografts and organoids model therapy response in prostate cancer
Sofia Karkampouna, Federico La Manna, Andrej Benjak, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 119
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue, Yukun Li, Xiaojuan Chen, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 116
Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy
Rosalinda Madonna, Stefania Moscato, Maria Concetta Cufaro, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 5, pp. 1175-1189
Closed Access | Times Cited: 51
Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics
Riya Thapa, Muhammad Afzal, Ahsas Goyal, et al.
Life Sciences (2024) Vol. 345, pp. 122613-122613
Closed Access | Times Cited: 27
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
A. Y. Kim, Salman Al Jerdi, Ryan B. MacDonald, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 22
Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)
Santa Cirmi, Asmae El, Louis Létinier, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 826-826
Open Access | Times Cited: 116
Proteomics and Machine Learning Approaches Reveal a Set of Prognostic Markers for COVID-19 Severity With Drug Repurposing Potential
Kruthi Suvarna, Deeptarup Biswas, Medha Gayathri J. Pai, et al.
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 69
Glioblastoma: Current Status, Emerging Targets, and Recent Advances
Amandeep Thakur, Chetna Faujdar, Ram Sharma, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8596-8685
Open Access | Times Cited: 69
Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer
Madhu Sharma, Avijit Kumar Bakshi, Naresh Mittapelly, et al.
Journal of Controlled Release (2022) Vol. 346, pp. 43-70
Closed Access | Times Cited: 49
Current status of drugs targeting PDGF/PDGFR
Jing-Yan Ai, Chenfu Liu, Wen Zhang, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 103989-103989
Closed Access | Times Cited: 13
Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers
Khine Shan, Shivani Dalal, Nyein Nyein Thaw Dar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 849-849
Open Access | Times Cited: 12
Application of a ImageJ-Based Method to Measure Blood Flow in Adult Zebrafish and Its Applications for Toxicological and Pharmacological Assessments
Ferry Saputra, Tzu-Ming Tseng, Franelyne P. Casuga, et al.
Biology (2025) Vol. 14, Iss. 1, pp. 51-51
Open Access | Times Cited: 1
Inhibitors of BRAF dimers using an allosteric site
Xiomaris M. Cotto-Rios, Bogos Agianian, Nadege Gitego, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 70
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Vinayak Palve, Yi Liao, Lily Rix, et al.
Seminars in Cancer Biology (2020) Vol. 68, pp. 209-229
Open Access | Times Cited: 68
Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection
Andreia Palmeira, Emı́lia Sousa, Aylin Köseler, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 6, pp. 132-132
Open Access | Times Cited: 61
Resistance to Molecularly Targeted Therapies in Melanoma
Meet Patel, Adam Eckburg, Shahina Gantiwala, et al.
Cancers (2021) Vol. 13, Iss. 5, pp. 1115-1115
Open Access | Times Cited: 53
Programmed cell death, redox imbalance, and cancer therapeutics
Xiaofeng Dai, Danjun Wang, Jianying Zhang
APOPTOSIS (2021) Vol. 26, Iss. 7-8, pp. 385-414
Closed Access | Times Cited: 50
The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention
Subhasmita Mahapatra, Nisha Amarnath Jonniya, Suman Koirala, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 41, Iss. 22, pp. 13509-13533
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top